A. Shah (London, United Kingdom), S. Chotirmall (Singapore, Singapore)
Aspergillus co-infection in critically ill COVID-19 patients
G. Pavliša (Zagreb, Croatia), I. Majdandzic (Zagreb, Croatia), A. Vukic Dugac (Zagreb, Croatia), M. Jankovic Makek (Zagreb, Croatia), L. Ljubicic (Zagreb, Croatia), M. Samarzija (Zagreb, Croatia)
|   |
Effect of omalizumab on glucocorticoid use, lung function and asthma control in the treatment of allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis
J. Douglass (Melbourne, Australia), M. Jin (Shanghai, China), J. Elborn (Belfast, United Kingdom), R. Agarwal (Chandigarh, India), W. J Calhoun (Texas, United States), X. Jaumont (Basel, Switzerland), S. Lazarewicz (Basel, Switzerland), M. Yan (Beijing, China)
| |
Anti-IgE therapy for management of recurrent ABPA exacerbations: successful outcome in 8 patients
M. Chopra (Kolkata, India), M. Chopra (KOLKATA, India), S. Babu Ps (KOLKATA, India)
| |
Aspergillus sensitization as a treatable trait in COPD
P. Tiew (Singapore, Singapore), J. Narayana (Singapore, Singapore), M. Quek (Singapore, Singapore), Y. Ang (Singapore, Singapore), F. Ko (Singapore, Singapore), M. Poh (Kuala Lumpur, Singapore), T. Jaggi (Singapore, Singapore), H. Xu (Singapore, Singapore), K. Thng (Singapore, Singapore), M. Koh (Singapore, Singapore), A. Tee (Singapore, Singapore), J. Abisheganaden (Singapore, Singapore), K. Tsaneva-Atanasova (Exeter, United Kingdom), F. Chew (Singapore, Singapore), S. Chotirmall (Singapore, Singapore)
| |
Azole resistance screening in Aspergillus species isolated from patients with COVID-associated pulmonary aspergillosis from Pakistan
S. Zaka (Karachi, Pakistan), J. Farooqi (Karachi, Pakistan), S. Faheem Naqvi (Karachi, Pakistan), K. Jabeen (Karachi, Pakistan), M. Irfan (Karachi (Sindh), Pakistan)
| |
Critical COVID-19 Associated Pulmonary Mucormycosis (CAPM): The underreported life-threatening spectrum of the Mucormycosis epidemic
S. Bansal (Bangalore, India), H. Kalpakam (Bangalore, India), P. Thakare (Bangalore, India), R. Mehta (Bangalore, India)
| |
Invasive fungal infections in COVID-19 patients from Pakistan
K. Jabeen (Karachi, Pakistan), N. Nasir (Karachi, Pakistan), J. Farooqi (Karachi, Pakistan), S. Ahsan Ali (Karachi, Pakistan), S. Faisal Mahmood (Karachi, Pakistan), N. Ghanchi (Karachi, Pakistan), M. Irfan (Karachi, Pakistan), R. Hasan (Karachi, Pakistan), A. Zafar (Karachi, Pakistan)
| |
Fungal infections in the ICU during the COVID-19 era
E. Koukaki (Athens, Greece), N. Rovina (Athens, Greece), K. Tzannis (Athens, Greece), S. Ampelioti (Athens, Greece), V. Romanou (Athens, Greece), A. Koutsoukou (Athens, Greece), G. Dimopoulos (Athens, Greece)
| |
Efficacy of LD Bio Aspergillus ICT Lateral flow assay for serodiagnosis of chronic pulmonary aspergillosis
A. Ray (New Delhi, India), M. Choudhury (New Delhi, India), P. Sethi (New Delhi, India), V. Meena (New Delhi, India), G. Singh (New Delhi, India), I. Xess (New Delhi, India), S. Sinha (New Delhi, India), N. Wig (New delhi, India), S. Kabra (New Delhi, India)
| |
Comparison of clinical features, risk factors and outcome of invasive pulmonary aspergillosis in critically ill COVID-19, influenza and community acquired pneumonia patients
S. Ali (Karachi (Sindh), Pakistan), K. Jabeen (Karachi (Sindh), Pakistan), J. Farooqi (Karachi (Sindh), Pakistan), S. Awan (Karachi (Sindh), Pakistan), M. Irfan (Karachi (Sindh), Pakistan)
| |
Absence of invasive mucormycosis in ventilated critically-ill COVID-19 patients: an autopsy study in a tertiary care university hospital
J. Schippers (Amsterdam, Netherlands), P. Verweij (Nijmegen, Netherlands), L. Heunks (Rotterdam, Netherlands), K. Van Dijk (Amsterdam, Netherlands)
| |
Late Breaking Abstract - Persistence of inflammatory and vascular damage mediators 5 months after acute COVID-19
N. Petousi (Oxford, United Kingdom), J. Melhorn (Oxford, United Kingdom), A. Alamoudi (Oxford, United Kingdom), M. Cassar (Oxford, United Kingdom), A. Fries (Oxford, United Kingdom), E. Fraser (Oxford, United Kingdom), A. Mentzer (Oxford, United Kingdom), B. Raman (Oxford, United Kingdom), N. Talbot (Oxford, United Kingdom)
| |
Late Breaking Abstract - Long-term follow-up of SARS-CoV-2 IgM and IgG production in the patients with COVID-19 in Japan
T. Matsunaga (Tokyo, Japan), S. Ohta (Tokyo, Japan), F. Yamaguchi (Tokyo, Japan), K. Suzuki (Tokyo, Japan), A. Tanaka (Tokyo, Japan), I. Tokimatsu (Tokyo, Japan), H. Sagara (Tokyo, Japan)
| |
Late Breaking Abstract - THE ROLE OF LABACS IN LONG COVID-19 PATIENTS IN PRINGSEWU, IND0NESIA
R. Soemarwoto (Bandar Lampung, Indonesia), P. Sari (Bandar Lampung, Indonesia), J. Oktabiannobel (Bandar Lampung, Indonesia), D. Ekawati (Bandar Lampung, Indonesia), A. Messah (Bandar Lampung, Indonesia), A. Wibowo (Bandar Lampung, Indonesia), I. Darmajati (Bandar Lampung, Indonesia)
| |
Late Breaking Abstract - Clinical performance evaluation of an anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay
J. Moore (Belfast, United Kingdom), L. Robertson (Belfast, United Kingdom), T. Ferguson (Belfast, United Kingdom), E. Cain (Belfast, United Kingdom), J. Goodman (Cambridge, United Kingdom), C. Colley (Cambridge, United Kingdom), M. Orr (Cambridge, United Kingdom), T. Moore (Belfast, United Kingdom)
| |
Late Breaking Abstract - Hospital-onset COVID-19 and antivirals
G. Khan (Maidstone, United Kingdom), M. Jeilani (Maidstone, United Kingdom), S. Bryant (Maidstone, United Kingdom), C. Butler (Maidstone, United Kingdom), E. Iossifidis (Maidstone, United Kingdom), S. Sleiman (Maidstone, United Kingdom), S. Moosavi (Maidstone, United Kingdom), J. Shoaib (Maidstone, United Kingdom), M. Szeto (Maidstone, United Kingdom)
| |
Late Breaking Abstract - The economic burden of pertussis among adults aged above 50 years, in England: post-hoc analyses of a retrospective database study in England
N. Jamet (Wavre, Belgium), E. Aris (Wavre, Belgium), J. De Melo (Wavre, Belgium), A. Ramond (London, United Kingdom), J. Simeone (Waltham, United States), V. Berlaimont (Waltham, United States)
| |
Late Breaking Abstract - Post-acute sequelae of SARS-CoV-2 among previously hospitalised individuals with COVID-19: a systematic literature review and meta-analysis>
J. Kelly (San Francisco, CA, United States), T. Curteis (Manchester, United Kingdom), A. Rawal (Boston, United States), M. Murton (London, United Kingdom), R. Shah-Gupta (Uxbridge, United Kingdom), A. Espinueva (Foster City, CA, United States), L. Chen (Foster City, CA, United States), M. Abdelghany (Foster City, CA, United States), D. Sweeney (San Diego, CA, United States), J. Quint (London, United Kingdom), R. Shah Gupta (LONDON, United Kingdom)
| |
Late Breaking Abstract - COVID-19 treatment and outcomes: trends over 20 months in 338,930 US hospital patients with COVID-19 and pneumonia
L. Chen (Foster City, United States), R. Gottlieb (Dallas, United States), A. Chandak (New York, United States), R. Haubrich (Foster City, United States), C. Der-Torossian (Foster City, United States), E. Lee (Foster City, United States), M. Thrun (Foster City, United States), J. Jarrett (Stockley Park, United Kingdom), A. Smith (Stockley Park, United Kingdom), A. Restuccia (Stockley Park, United Kingdom), S. Hollemeersch (Stockley Park, United Kingdom), S. Sandhu (Foster City, United States), T. Oppelt (Foster City, United States), P. Herscu (Lorrach, Germany), R. Gupta (Stockley Park, United Kingdom)
| |
Late Breaking Abstract - A randomized study to evaluate safety and pharmacokinetics of CT-P63 in healthy subjects
M. Tomaszewska-Kiecana (Jozefow, Poland), A. Wolowik (Jozefow, Poland), A. Kulesza (Jozefow, Poland), K. Ahn (Incheon, Republic of Korea), N. Jung (Incheon, Republic of Korea), Y. Lee (Incheon, Republic of Korea), J. Kim (Incheon, Republic of Korea), S. Kim (Incheon, Republic of Korea), M. Nowicki (Jozefow, Poland)
| |